Dupixent Lawsuits and Claims of Cutaneous T-Cell Lymphoma

For patients living with severe eczema, Dupixent arrived as a lifeline. After years of failed steroid creams, immunosuppressants, and treatments that offered little more than temporary relief, this biologic therapy promised something different. It was a targeted solution that addressed the root of chronic inflammation rather than just its symptoms, delivering clear skin and making life manageable once again.

Some patients were finally able to sleep properly after years of suffering.

But for a growing number of patients, Dupixent may have inadvertently contributed to the delayed detection or progression of underlying conditions linked to Cutaneous T-cell lymphoma (CTCL).

Across the United States, lawsuits are emerging that allege a deeply troubling possibility that Dupixent may be linked to the development, progression, or misdiagnosis of CTCL, which is a rare cancer that, in its early stages, can look almost identical to eczema. Some plaintiffs allege they spent months or years being treated for the wrong condition entirely, while an underlying lymphoma quietly advanced.

These concerns have sparked intense scrutiny and a growing wave of litigation. Central to these cases are two closely linked questions: did Dupixent influence cancer risk, and did its manufacturers adequately warn physicians and patients about that possibility? Plaintiffs argue that incomplete or delayed warnings may have contributed to misdiagnosis or delayed detection, potentially allowing disease to progress before appropriate treatment was initiated.

It is this intersection of evolving medical evidence, diagnostic complexity, and disclosure obligations that makes these lawsuits both unusually complex and potentially far-reaching.

How Dupixent Works (It’s Important Legally)

Mechanistically, Dupixent works by blocking interleukin-4 (IL-4) and interleukin-13 (IL-13), two cytokines that play a central role in Type 2 inflammatory responses. By inhibiting these pathways, it reduces the immune activity responsible for the hallmark symptoms of atopic dermatitis, which includes redness, itching, skin barrier breakdown, and chronic flaring that make severe eczema so debilitating.

This precision is what distinguished the drug from older systemic treatments like cyclosporine or methotrexate, which suppressed the immune system more broadly and carried well-documented risks of long-term toxicity. Dupixent offered a steroid-sparing, long-term option that physicians and patients could feel more confident about, at least based on what was known at the time.

However, the same mechanism that made Dupixent appealing is now at the center of litigation. The immune system does more than regulate inflammation: it also performs immune surveillance, which is the ongoing process by which the body identifies and eliminates abnormal or potentially malignant cells. IL-4 and IL-13 signaling are involved not just in allergic responses but in broader immune regulation, including the behavior of T-cells.

Dupixent’s interference with those pathways raises a question that is now being argued in courtrooms: could long-term suppression of these signals impair the body’s ability to detect and control the kind of abnormal T-cell proliferation that characterizes Cutaneous T-cell lymphoma?

From Breakthrough Drug to Legal Scrutiny

For most of its commercial life, Dupixent’s safety profile was considered favorable. Clinical trials reported relatively modest side effects, including injection site reactions, conjunctivitis, and rare cases of eosinophilia. There was nothing that significantly tempered enthusiasm for the drug, so Sanofi and Regeneron marketed Dupixent aggressively.

The first signals that something might be wrong emerged not from clinical trials but from real-world use at scale. As the patient population grew into the hundreds of thousands, rare adverse outcomes began to surface that would not normally appear in large, long-term pre-approval studies. Reports of patients developing CTCL, or being diagnosed with it after years on Dupixent, started accumulating in adverse event databases and medical literature.

Crucially, CTCL is a cancer that can mimic eczema with striking accuracy in its early stages. Both conditions produce red, scaly, itchy patches of skin. Both can flare and remit, and both respond (temporarily) to similar topical treatments. That overlap created a dangerous diagnostic blind spot where patients already diagnosed with eczema and placed on Dupixent had little reason to question whether their condition might actually be something else. Physicians managing what they believed to be an inflammatory condition had little reason to biopsy aggressively for malignancy.

This is the backdrop against which these lawsuits were filed, and it makes these cases far more complicated than a conventional failure-to-warn cases that we typically see in defective drugs cases. Plaintiffs are alleging that the drug’s use, combined with inadequate warnings and a condition that naturally obscures its own misdiagnosis, may have cost patients the window of time in which early intervention could have mattered most.

CTCL Misdiagnosis in Dupixent Lawsuits

Cutaneous T-cell lymphoma (CTCL) is a rare form of lymphoma that primarily affects the skin and is often difficult to identify in its early stages. One of the central challenges is that early CTCL can closely resemble common conditions like eczema, presenting with red patches, scaling, itching, and inflammation.

Because of this overlap, diagnosis is frequently delayed. Confirming CTCL typically requires repeated biopsies and clinical observation over time, which are steps that may not be immediately pursued when symptoms appear consistent with a benign dermatological condition. As a result, the disease can progress while being treated as something less serious.

This diagnostic complexity sits at the heart of litigation involving Dupixent. Many plaintiffs describe a similar progression of events: an initial eczema diagnosis, treatment with Dupixent, followed by symptoms that persist, evolve, or fail to respond as expected. In some cases, further testing eventually revealed CTCL at a more advanced stage than if it had been identified earlier.

Accordingly, plaintiffs allege that Dupixent, particularly its effect on inflammation, may alter how the disease presents, potentially reducing visible symptoms without addressing the underlying condition. This, they argue, could delay further diagnostic investigation.

Secondly, some claims also assert that immune modulation may influence disease progression, particularly in a condition involving malignant T-cells. While this remains an area of ongoing scientific study, it forms part of the broader argument that risks associated with delayed diagnosis or disease progression should have been more clearly communicated.

From a legal standpoint, the key issue is not whether Dupixent definitively causes CTCL, but whether the manufacturers knew, or should have known, about these potential risks, and whether physicians and patients were adequately warned.

At this point, scientific proof is not required because courts do not require absolute proof of causation. Instead, they consider whether a risk was reasonably foreseeable and whether sufficient warnings were provided. In this context, the patterns of delayed diagnoses following treatment or unexpected disease progression can be enough to support a claim, even as scientific research continues to evolve.

For a free legal consultation, call (725) 900-9000

Dupixent Lawsuits: April 2026 Update

Litigation involving Dupixent continues to expand across multiple jurisdictions as plaintiffs bring product liability claims against Sanofi and Regeneron Pharmaceuticals. As of early 2026, these lawsuits are being filed as individual actions rather than as a certified class action, meaning each case is evaluated on its own facts, particularly the patient’s medical history, treatment timeline, and diagnostic progression.

Although the cases are individualized, a consistent factual pattern has begun to emerge. Many plaintiffs report being diagnosed with moderate-to-severe eczema and prescribed Dupixent after other treatments failed. In the months or years that followed, their condition either failed to improve as expected or evolved in atypical ways such as spreading, thickening, or becoming resistant to treatment. Eventually, further testing, often including multiple biopsies, led to a diagnosis of cutaneous T-cell lymphoma (CTCL), sometimes at a more advanced stage than might have been expected with earlier detection.

This pattern is central to the legal theory underlying many of these claims. Plaintiffs argue that the drug may have altered the presentation of the disease, masked symptoms, or contributed to delayed diagnosis. These factors, when taken together, may have allowed the condition to progress unchecked.

Current State of Dupixent Litigation

Most lawsuits involving Dupixent center on failure-to-warn claims. Plaintiffs allege that Sanofi and Regeneron Pharmaceuticals did not adequately disclose the potential risks associated with CTCL, including the possibility of misdiagnosis as eczema and the need for closer monitoring when symptoms fail to respond as expected. Some claims also argue that manufacturers failed to update safety warnings in light of emerging post-market data and case reports.

A key issue in these cases is “signal recognition,” a question on whether the manufacturers identified and acted on early indications of a potential risk. Internal documents, adverse event reports, and post-market surveillance data can help determine whether these risks were reasonably knowable and whether warnings were sufficient.

So far, the litigation remains in an early stage, with cases filed in federal courts and no consolidation reported yet. Since the lawsuits are proceeding individually, outcomes will depend on case-specific evidence and jurisdiction. This also means potential claimants do not need to wait for a class action to move forward.

At this stage, courts have not reached definitive conclusions on causation, and research into the relationship between Dupixent and CTCL is ongoing. However, the consistency of allegations and the growing number of filings indicate that this is an active and evolving area of product liability litigation.

Who May Have a Viable Dupixent Claim

If you or a loved one developed CTCL after using Dupixent, you may have a viable claim based on medical history, timing, and how the disease developed in relation to treatment. Courts and attorneys are currently focused on the sequence of events leading to the diagnosis: what was known, what changed, and whether earlier intervention may have been possible.

In general, patients who used Dupixent and were later diagnosed with Cutaneous T-cell lymphoma (CTCL) may have grounds for a claim, particularly if there was no prior history of lymphoma before starting treatment.

Stronger claims often involve evidence that diagnosis was delayed or that the disease progressed during the course of treatment. This may include situations where:

• symptoms worsened or changed after starting Dupixent
• multiple biopsies were required before CTCL was identified
• treatment continued despite a lack of expected response
• diagnosis occurred at a later or more advanced stage

In these cases, plaintiffs typically argue that earlier recognition, or different clinical decision-making, could have altered the outcome. The focus is not always on whether Dupixent directly caused cancer, but whether it contributed to a delay in diagnosis or progression of an existing condition.

Taking the First Step

For patients affected by Dupixent and their families, the starting point to seeking justice is simple: gather records, document when symptoms began and how they changed, and identify when Dupixent was introduced into the treatment plan.

From there, a legal evaluation can help determine whether those facts align with known patterns in Dupixent litigation. These cases are complex, and small details can make a significant difference in how they are assessed.

Van Law Firm has experienced Defective Drug Lawyers who focus on complex pharmaceutical and product liability cases, including claims involving drugs like Dupixent. Our firm is actively investigating the link between Dupixent use and Cutaneous T-cell lymphoma (CTCL) to determine what legal remedies are out there for patients. With a deep understanding of the medical and legal issues involved, we can help you evaluate your case, gather the necessary evidence, and navigate the process with confidence. Reach out today for a free consultation to take the first step toward pursuing justice.